The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-26

Study Completion Date

2018-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The global burden of sepsis is substantial with an estimated 15 to 19 million cases per year; the vast majority of these cases occur in low income countries. New therapeutic approaches to sepsis are desperately required; considering the global burden of sepsis these interventions should be effective, cheap, safe and readily available. The aim is to study the synergistic effect of vitamin C, hydrocortisone and thiamine on survival in patients with severe sepsis and septic shock.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock

NCT05192213

Sepsis Septic Shock

TERMINATED PHASE3

Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock

NCT03540628

Septic Shock

COMPLETED NA

Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock

NCT03380507

Septic Shock Critical Illness

TERMINATED PHASE2/PHASE3

Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock

NCT03649633

Septic Shock

TERMINATED PHASE1/PHASE2

Vitamin C, Hydrocortisone and Thiamine for Septic Shock

NCT03592693

Shock, Septic

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AIM OF THE STUDY:

The goal is to determine the effects on clinical course and outcome of patients with severe sepsis and septic shock treated with vitamin C, hydrocortisone and thiamine.

BACKGROUND:

This study will be conducted in the intensive care unit of Department of Gastroenterology, University Medical Center (UMC) Ljubljana. All of the patients with severe sepsis and septic shock admitted to the Intensive Care Unit (ICU) in the past 12 hours will be screened for possible inclusion in the study. The diagnosis of severe sepsis and septic shock will be based on the 1992 American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions.

PLAN OF THE STUDY:

After determining the eligibility for inclusion in our study, the investigators will acquire the written consent from the patient or relatives. The investigators (doctor on call) will randomize the patient either in the treatment or placebo group. The randomization will be done before-hand with the online tool Research Randomizer. After acquiring the randomized numbers, they will be placed in sealed envelopes. These envelopes will be available to the on-call doctor. The envelopes will then be sent to our outpatient clinic, where the studied substances will be mixed by a nurse, that will have no contact with the patients or the ICU staff. The substances will be marked with Vitamin C, Thiamine and Hydrocortisone, regardless if normal saline or the actual substances are inside the vials. Only this nurse will have the data regarding the contents of the vials.

Based on literature the investigators expect that survival and clinical course in sepsis and septic shock is correlated with fluid resuscitation and vasopressor use. Because of this, all of the included patients will be monitored with invasive hemodynamic monitoring (All of the patients will be monitored with the Edwards EV 1000 monitors).

All of the patients will be treated the same as per internationally recognized guidelines for treatment of septic shock. While the use of corticosteroids in severe sepsis is off-label, the patients will be informed of possible side-effects. This fact will also be written in the consent.

Neither the patients or the relatives will receive no financial compensation for study inclusion. During the hospitalization, the patients will receive three different substances in dosages, that are non toxic. During the study, there will be intermittent statistical analysis, and if increased mortality or severe side effects will be found then the study will be terminated. The confidentiality of personal data will be protected accordingly with the rules and laws of patient's privacy. The identity of patients will not be disclosed. The data acquired during the study will be available to the study participant. The anticipated costs will be covered by the Department of Gastroenterology, UMC Ljubljana. No financial compensation will be given to researchers.

During the study the following data will be acquired from the patients:

1. Age,
2. Sex,
3. Body weight,
4. Admitting diagnosis and source of infection,
5. Isolated pathogens,
6. Comorbidities,
7. The need for mechanical ventilation,
8. The use of vasopressors (all doses will be converted to Norepinephrine equivalents),
9. The duration of vasoactive therapy,
10. Daily urine output,
11. Fluid balance after 24 and 72 hours,
12. The presence of acute kidney failure
13. Duration of ICU stay and hospital stay,
14. Survival in ICU, hospital, after 28 and 60 days
15. Routine blood test for the first 4 days, a. creatinine b. White Blood Cells (WBC) c. Platelets d. Bilirubin e. Partial Pressure of Oxygen in Arterial Blood/Fraction of Inspired Oxygen (PaO2/FiO2) ratio e. procalcitonin (PCT) and procalcitonin clearance f. lactate g. blood samples will be stored for possible additional analysis

The patients' admission Acute Physiology and Chronic Health Evaluation (APACHE) II and APACHE IV scores will be recorded. The APACHE IV score allows calculation of the predicted hospital mortality and predicted ICU length of stay (LOS). The daily Sepsis-related Organ Failure Assessment (SOFA) score will be recorded for the first 4 treatment days.

Data analysis:

Summary statistics will be used to describe the clinical data and presented as mean ± standard deviation (SD), median with interquartile range (IQR) or percentages as appropriate. Chi squared analysis with Fisher's exact test (when appropriate) and Student's t test (Mann Whitney U test for non-normal distributions) were used to compare data between the active treatment group and the placebo group with statistical significance declared for probability values of 0.05 or less.

Data Safety \& storage:

The main risk to subjects is the accidental release of Protected Health Information (PHI). Careful record management methods will be in place to ensure this type of privacy breach does not occur. The data set will be kept in a password-protected file and stored separately from the subject identification (ID) key in the locked office of the principal investigator. Only the research team will have access to this information, and will not disclose this information to any other person or entity. Three years after the completion of the study, all collected data will be destroyed by permanently deleting electronic copies.

EXPECTED RESULTS:

The investigators expect a faster recovery, shorter hospitalization, shorter use of vasoactive drugs and better survival in treatment group versus (vs.) control group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Septic Shock Critical Illness Fluid Overload

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active substances

Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.

Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.

Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge.

Group Type EXPERIMENTAL

Vitamin C

Intervention Type DRUG

Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.

Hydrocortisone

Intervention Type DRUG

Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.

Thiamine

Intervention Type DRUG

Intravenous thiamine will be applied as per instructions described in arm/group descriptions.

Control

Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.

Group Type PLACEBO_COMPARATOR

0.9% Sodium Chloride Injection

Intervention Type DRUG

0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin C

Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.

Intervention Type DRUG

Hydrocortisone

Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.

Intervention Type DRUG

Thiamine

Intravenous thiamine will be applied as per instructions described in arm/group descriptions.

Intervention Type DRUG

0.9% Sodium Chloride Injection

0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ascorbic Acid Corticosteroids B1 Vitamin Normal Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of severe sepsis or septic shock within 12 hours of admission in our Intensive Care Unit (ICU).
* Informed consent.

Exclusion Criteria

* Age \< 18 years
* Pregnancy
* Do Not Resuscitate (DNR/DNI) with limitations of care
* Patients with fatal underlying disease who are unlikely to survive to hospital discharge (e.g.: disseminated malignant disease)
* Patients primarily admitted for acute coronary syndromes, acute cerebrovascular incidents or active gastrointestinal (GI) bleeds
* Patients that need immediate surgical treatment
* Patients with HIV and a cell count of cluster of differentiation 4 (CD4) cells \< 50 mm2,
* Patients with known glucose-6 phosphate dehydrogenase (G-6PD) deficiency.
* Patients with severe sepsis/septic shock transferred from another hospital
* Patients with features of sepsis/septic shock \> 24 hours
* Patients who require treatment with corticosteroids for an indication other than sepsis (chronic corticosteroid use, known Addison's Disease, Ulcerative colitis, Crohn's disease...)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No